PRKDC and Miyoshi myopathy: NU7441, a DNA-PK inhibitor, shows minimal single-agent efficacy but cooperates with MRE11 inhibition to block compensatory DNA repair, highlighting potential for dual-targeting strategies in MM with high replication stress (39).